Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Predictors of Antidepressant Response of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression
FY 2023-24
Summary
Bipolar Disorder (BD) is a severe mental illness that affects about 2-3% of people over a lifetime. Currently, pharmacological and psychological treatments are the first choice for BD, but about one-third of patients do not respond and are treatment-resistant (TRBD). TRBD is associated with significantly greater depression severity, risk of suicide, relapse, and functional impairment. There is a need for additional safe options to treat TRBD when first-line treatments are ineffective. Ketamine is a dissociative anesthetic that, in subanesthetic doses, has been used to treat depression. Repeated intravenous (IV) infusions of ketamine have provided reductions in depression symptoms, including severe cases of treatment-resistant depression (Major Depressive Disorder). However, further research is required in TRBD patients and it is unclear what factors can be used to predict the effectiveness of ketamine in BD patients. Factors such as age, baseline psychiatric symptoms, number of past medication trials, and body mass index will be investigated as potential baseline predictors of the efficacy of ketamine infusions. Antidepressant treatment response, adverse effects, and dissociation after the first infusion also serve as possible predictors. This research project aims to evaluate potential predictors by analyzing data from an ongoing randomized controlled trial investigating IV ketamine infusions for TRBD. This project can provide significant insights into determining who among TRBD patients is most likely to respond to IV ketamine treatment to better inform clinical practices and move towards personalized, precision-based care rather than the current standard, trial-and-error approach.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
505917
Name
Chisamore Noah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Predictors of Antidepressant Response of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antidepressant; Bipolar Disorder; Depression; Ketamine; Mood Disorders; Predictors
Abstract
Bipolar Disorder (BD) is a severe mental illness that affects about 2-3% of people over a lifetime. Currently, pharmacological and psychological treatments are the first choice for BD, but about one-third of patients do not respond and are treatment-resistant (TRBD). TRBD is associated with significantly greater depression severity, risk of suicide, relapse, and functional impairment. There is a need for additional safe options to treat TRBD when first-line treatments are ineffective. Ketamine is a dissociative anesthetic that, in subanesthetic doses, has been used to treat depression. Repeated intravenous (IV) infusions of ketamine have provided reductions in depression symptoms, including severe cases of treatment-resistant depression (Major Depressive Disorder). However, further research is required in TRBD patients and it is unclear what factors can be used to predict the effectiveness of ketamine in BD patients. Factors such as age, baseline psychiatric symptoms, number of past medication trials, and body mass index will be investigated as potential baseline predictors of the efficacy of ketamine infusions. Antidepressant treatment response, adverse effects, and dissociation after the first infusion also serve as possible predictors. This research project aims to evaluate potential predictors by analyzing data from an ongoing randomized controlled trial investigating IV ketamine infusions for TRBD. This project can provide significant insights into determining who among TRBD patients is most likely to respond to IV ketamine treatment to better inform clinical practices and move towards personalized, precision-based care rather than the current standard, trial-and-error approach.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chisamore, Noah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~